Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: michaele23 who wrote (1250)	6/1/2000 11:28:00 AM
From: Starlight	Read Replies (1) \| Respond to of 1605

I listened to the interview -- everyone should take the time to do so. It only runs about 10 min. It was very upbeat. biz.yahoo.com Here are just a few notes: They have finished the safety study (for CHF) and will present it to the FDA in the next few weeks. EECP in early studies seems to reduce Emergency Room visits for congestive heart failure (CHF). The treatment is for 1 hr./day, 5 days/week for 7 weeks. Cost is about $6,000 vs. $40,000 for surgical procedures to treat CHF. They're already cleared by the FDA to treat angina. (300,000 patients per year in the US have angina.) About 110 centers in the US are using EECP now. Only 35 patients per year can be treated by ONE system. (I hope I got these numbers right.) They've recently added to the sales force -- now have 20 - up from 5. ----------- It looks to me likes there's plenty of room to grow. If the company gets the word out and national media pick up on it, people will start demanding that they be treated by EECP. I compare this to what happened with laproscopic surgery. It is now done extensively, and it has reduced hospital stays, costs, recovery time, etc. EECP could do the same. Betty